YOLFTbeta
Mendus AB (publ)

Mendus AB (publ)

IMMU · ST · Healthcare / Biotechnology

4.36SEK-0.13 (-3.01%)

Price History

Full chart

Market Stats

Previous Close4.49
Open4.49
Day Range4.36 – 4.80
52-Week Range3.86 – 8.49
Volume29.29K
Market Cap393.60M
P/E (TTM)0.00
Forward P/E0.45
EPS-1.80
Dividend Yield0.00%
Beta0.76
50-Day Avg6.82
200-Day Avg5.69

About

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Erik Manting Ph.D.
  • Employees19
  • HeadquartersVästra Trädgårdsgatan 15, Stockholm, Sweden, 111 53, Sweden
  • Websitehttps://www.mendus.com

Leadership

  • Dr. Erik Manting Ph.D.Chief Executive Officer · b. 1971
  • Ms. Lotta FermChief Financial Officer · b. 1966
  • Dr. Tariq Mughal M.D.Chief Medical & Scientific Officer

Financials

Income Statement

Currency: SEK2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--5.00K-00000016.67M06.00K3.00M28.49M5.05M0
Growth (%)------------100.00%-+49816.67%+851.15%-82.28%-100.00%
Cost of Revenue--2.70M-083.81K080.79K71.19K60.00K1.64M1.77M1.85M4.85M6.30M6.52M6.29M
Gross Profit---2.70M-0-83.81K0-80.79K-71.19K-60.00K15.03M-1.77M-1.84M-1.85M28.49M-6.52M-6.29M
Gross Margin---53926.28%-------90.17%--30750.00%-61.87%100.00%-129.14%-
Operating Expense---2.51K-16.65M36.32M43.64M73.39M80.63M97.79M147.36M84.25M128.25M131.83M129.14M128.63M113.97M
Operating Income-2.31M-2.71M-2.69M-6.97M-16.65M-36.40M-43.64M-73.47M-80.70M-97.85M-132.32M-86.03M-130.10M-133.68M-100.65M-135.15M-120.26M
Operating Margin---53876.00%--------793.79%--2168333.33%-4463.57%-353.32%-2677.20%-
EBITDA-2.28M-2.65M-4.30M-6.84M-16.10M-35.51M-43.54M-73.33M-80.63M-97.85M-43.22M-84.25M-128.28M-128.67M-97.85M-120.66M-113.97M
EBITDA Margin---85921.16%--------259.26%--2137916.67%-4296.26%-343.48%-2390.27%-
Net Income-2.29M-2.67M-2.63M-6.89M-16.18M-35.61M-43.92M-73.59M-80.34M-97.86M-135.71M-92.47M-136.69M-136.99M-101.62M-128.40M-113.26M
Net Income Margin---52586.50%--------814.09%--2278233.33%-4573.99%-356.72%-2543.56%-
R&D------57.81M57.81M57.81M70.93M103.14M47.88M85.80M87.05M92.65M101.08M85.06M
R&D as % of Total Revenue----------618.74%-1429933.33%2906.48%325.25%2002.28%-
Interest Expense8.62K19.79K34.41K32.78K27.24K23.82K17.33K0273.50K14.00K17.00K3.22M3.28M5.26M3.12M1.22M3.28M
Interest Expense % of Total Revenue--688.16%-------0.10%-54733.33%175.76%10.93%24.15%-

Balance Sheet

Currency: SEK2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.68M6.25M9.27M26.70M109.54M71.03M154.24M121.57M246.15M450.37M303.83M728.66M720.98M620.39M755.95M696.36M628.32M
Total Liabilities1.09M2.33M1.65M2.09M9.29M6.41M15.06M19.18M56.59M44.33M31.05M67.57M64.24M105.95M51.23M51.22M43.26M
Total Equity6.59M3.92M7.63M24.60M100.24M64.63M139.18M102.39M189.56M406.04M272.78M661.09M656.74M514.44M704.73M645.15M585.07M
Cash6.32M4.32M5.75M25.61M107.53M32.27M119.38M102.90M128.32M443.80M296.81M167.64M155.31M41.85M120.78M101.91M64.66M
Total Debt850.00K850.00K850.00K850.00K850.00K850.00K850.00K850.00K850.00K850.00K2.10M35.04M36.98M78.16M24.49M22.71M18.85M
Net Debt-5.47M-3.47M-4.90M-24.76M-106.68M-31.42M-118.53M-102.05M-127.47M-442.95M-295.96M-132.60M-118.34M36.31M-96.29M-79.20M-45.81M

Cash Flow

Currency: SEK2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.67M-3.23M-7.15M-9.28M-40.10M-40.23M-33.74M-46.45M-104.67M-145.81M-56.63M-138.03M-109.33M-162.76M-79.67M-81.53M
Investing Cash Flow-334.87K-1.67M-57.89K-298.06K-35.00M25.65M25.65M10.16M-809.00K-251.00K157.30M-1.36M-12.32M-442.00K-1.58M-734.00K
Financing Cash Flow-6.34M27.06M91.81M101.79M101.79M16.69M62.27M419.58M756.00K50.90M127.03M8.19M242.10M61.52M45.18M
Capital Expenditure333.87K1.67M57.89K298.06K000809.00K809.00K809.00K464.00K1.36M12.10M1.82M1.83M307.00K
Free Cash Flow-2.00M-4.90M-7.20M-9.58M-40.10M-40.23M-33.74M-46.45M-104.67M-146.62M-57.09M-139.39M-121.43M-164.58M-81.51M-81.84M
FCF to OCF120.04%151.62%100.81%103.21%100.00%100.00%100.00%100.00%100.00%100.55%100.82%100.99%111.06%101.12%102.30%100.38%

Earnings

Report DateMar 31, 2014Sep 17, 2014Nov 18, 2014Feb 20, 2015May 21, 2015Sep 18, 2015Nov 18, 2015Feb 19, 2016May 20, 2016Aug 31, 2016Feb 17, 2017May 19, 2017Aug 18, 2017Nov 17, 2017Feb 16, 2018May 4, 2018Aug 17, 2018Nov 7, 2018Feb 15, 2019Apr 25, 2019Aug 20, 2019Nov 6, 2019Feb 18, 2020Apr 28, 2020Aug 27, 2020Nov 5, 2020Feb 18, 2021May 4, 2021Aug 26, 2021Oct 28, 2021Feb 17, 2022May 10, 2022Aug 26, 2022Nov 11, 2022Feb 17, 2023May 12, 2023Aug 29, 2023Nov 9, 2023Feb 14, 2024May 17, 2024Aug 23, 2024Nov 8, 2024Feb 13, 2025May 6, 2025Aug 21, 2025Nov 13, 2025Feb 11, 2026May 8, 2026Aug 19, 2026
EPS Estimate----------0.00----------------------------0.98-0.60-0.62-0.70-0.75-0.73-0.54-0.66-0.83--0.45
EPS Actual-5.67-0.25-0.28-0.49-0.48-0.35-0.35-0.52-0.43-0.69-0.90-0.74-12.71-0.78-0.73-0.60-0.38-0.46-0.50-0.32-0.36-0.32-0.46-0.34-0.29-0.24-0.29-0.25-0.19-0.13-0.16-0.14-0.15-0.19-0.22-0.15-0.02-0.05-0.05-0.80-0.76-0.46-0.63-0.61-0.45-0.37-0.74-0.34-0.34
Surprise--------------------------------------95.13%-33.33%-22.58%34.29%16.00%16.44%16.67%43.94%10.84%-24.44%
Timing-After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hours-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hours

Key Statistics & Ratios

Market Cap393.60M
Enterprise Value384.44M
Trailing P/E0.00
Forward P/E0.45
PEG Ratio0.00
Price / Sales190.33
Price / Book0.78
EPS-1.80
Book Value8.51
Revenue (TTM)-1.44M
Gross Profit (TTM)-1.44M
EBITDA-92.61M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-17.94%
Return on Assets-9.74%
Shares Outstanding63.48M
Shares Float23.04M
Beta0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 3, 20241:20
  • Jul 10, 20231343:1237
  • Dec 5, 2017667:622
  • May 24, 2016335:323
  • Apr 9, 201450:47